Stock Analiz

Neuphoria Therapeutics Inc. NEUP

Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026

$2.55Market cap $14M
Open the interactive analysis →

Neuphoria Therapeutics Inc. (NEUP) is a healthcare company listed in the US with a market value of about $14M. In fiscal year 2026 it had revenue of $1M and net income of -$13M, a net margin of -1145.7%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -67%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 98% below the current price.

About Neuphoria Therapeutics

Neuphoria Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. Revenue went from $14609 in 2023 to $1M in 2026, growth of about 331.6% a year. It was profitable in 3 of the last 7 years in our data.

Score: 1.0 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • 3-year revenue growth above 10% a year
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S11.8
P/B0.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−98%

Growth and quality

Revenue growth (1 yr)-92.5%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-49182.7%
ROIC (5-yr avg.)-67.2%
Profitable years (of last 10)3
Years paying a dividend—

Financials, last 7 years

Fiscal year2026202520242023202220212020
Revenue$1M$16M—$14609———
Net income-$13M-$369632-$15M-$21M$628352$669049$941330
Free cash flow————-$15M-$6M-$3M
EPS (diluted)$-2.49$-0.07$-2.86$-3.95$0.12$0.12$0.17
Net margin-1145.7%-2.4%—-146400.0%———
ROIC-66.2%-4.7%-100.4%-97.7%———

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Neuphoria Therapeutics stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 98% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Neuphoria Therapeutics pay a dividend?

Not currently.

Is Neuphoria Therapeutics a good stock to buy?

We do not give buy or sell advice. Neuphoria Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.